ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cleveland Clinic Invests In Small Firm

by Ann M. Thayer
August 10, 2009 | APPEARED IN VOLUME 87, ISSUE 32

Cleveland Clinic, a leading academic medical center, has taken an equity stake in FTA Therapeutics, a Pennsylvania-based developer of antimicrobials, in return for conducting clinical studies with FTA. The studies will be part of a project between FTA and biotech firm Pure Bioscience focused on a silver dihydrogen citrate (SDC) antimicrobial. FTA is completing preclinical work on SDC formulations to prepare for trials on wound care and acne later this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment